Tribunal Upholds CIT(A) on Section 35(2AB) Deductions, MAT Credit, Education Cess; Partly Allows Revenue on R&D

The Tribunal upheld the CIT(A)'s decisions on weighted deductions under Section 35(2AB) and MAT credit computation. It allowed the Revenue's ground on the non-deductibility of Education Cess. Additionally, the Tribunal partly allowed the Revenue's grounds on the netting off of income from R&D expenses.

---

---

Issues Involved:

1. Weighted deduction under Section 35(2AB) of the Income Tax Act for Clinical Trial Expenses, Quality Control/Testing Expenses, and Consultancy Fee Expenses.
2. Deduction of R&D Expenses on a gross basis without netting off income from R&D products and assets.
3. Deduction for Education Cess under Section 37(1) of the Act.
4. MAT credit computation including surcharge and cess.

Issue-wise Detailed Analysis:

1. Weighted Deduction under Section 35(2AB):

The Revenue challenged the CIT(A)'s decision to allow weighted deductions at 200% for Clinical Trial Expenses, Quality Control/Testing Expenses, and Consultancy Fee Expenses. The Tribunal upheld the CIT(A)'s decision, referencing multiple precedents, including ACIT vs. Crompton Greaves Ltd. and CIT vs. Cadila Healthcare Ltd., which established that prior to 01.07.2016, DSIR approval of the quantum of expenditure was not required, only the R&D facility needed approval. The Tribunal also noted that Clinical Trial Expenses incurred outside the R&D facilities were eligible for deduction, following the Gujarat High Court's interpretation. Consequently, the Tribunal dismissed the Revenue's grounds on this issue.

2. Deduction of R&D Expenses on Gross Basis:

The CIT(A) allowed the Assessee's claim for R&D expenses on a gross basis without netting off income from R&D products and assets, relying on the Tribunal's previous decisions in the Assessee's own case and others like Microlabs Ltd. and Wockhardt Ltd. The Tribunal affirmed that only sales realization from R&D assets should offset R&D expenses, not sales from R&D products. Thus, the Tribunal partly allowed the Revenue's grounds, permitting the reduction of sale proceeds from R&D assets but not from R&D products.

3. Deduction for Education Cess:

The Tribunal noted the retrospective amendment by the Finance Act 2022, which included surcharge and cess within the definition of 'tax' under Section 40(a)(ii) of the Act. Therefore, it ruled that no deduction for Education Cess was allowable for the Assessment Year 2014-15, allowing the Revenue's ground on this issue.

4. MAT Credit Computation:

The Revenue contested the CIT(A)'s decision to include surcharge and cess in MAT credit computation. The Tribunal referred to multiple precedents, including the Kolkata Bench's decision in Bhagwati Oxygen Ltd. and the Mumbai Bench's decision in Tata Motors Ltd., which supported the inclusion of surcharge and cess in MAT credit computation. The Tribunal affirmed that surcharge and education cess should be included for determining MAT credit, dismissing the Revenue's ground on this issue.

Conclusion:

The Tribunal's decision resulted in a mixed outcome for the Revenue. It upheld the CIT(A)'s decisions on weighted deductions under Section 35(2AB) and MAT credit computation, while allowing the Revenue's ground on the non-deductibility of Education Cess. The Tribunal also partly allowed the Revenue's grounds on the netting off of income from R&D expenses.

---